Bronchospasm induced by bevacizumab

Bevacizumab has a lower risk of treatment‐related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year‐old man with lung adenocarcinoma and childhood asthma...

Full description

Saved in:
Bibliographic Details
Published in:Respirology case reports 2013-09, Vol.1 (1), p.14-16
Main Authors: Taniguchi, Hirokazu, Tsuchida, Tomoko, Nakamura, Yoichi, Motoshima, Kohei, Mizoguchi, Kosuke, Kohno, Shigeru
Format: Article
Language:English
Subjects:
Asthma
Bronchodilators
Cancer therapies
Case reports
Chemotherapy
Dyspnea
Hypoxia
Immunoglobulins
Immunotherapy
Lung cancer
Metastasis
Monoclonal antibodies
Outpatient care facilities
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bevacizumab has a lower risk of treatment‐related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year‐old man with lung adenocarcinoma and childhood asthma. Then, grade 3 hypoxia developed and improved spontaneously. This reversible obstructive lung disorder was confirmed using a flow‐volume loop, and the patient was diagnosed as having a bronchospasm due to infusion reaction of bevacizumab. This bronchospasm was easily manageable and preventable using an oral bronchodilator and an inhalant combination product, and the patient continued with bevacizumab therapy until the disease progression.
ISSN:2051-3380
DOI:10.1002/rcr2.10